SHENYANG, China, May 5 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ('3SBio' or 'the Company'), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Ernst & Young Hua Ming ('Ernst & Young') as the Company's independent registered public accounting firm.

Ernst & Young replaces KPMG, previously the independent auditor for 3SBio. Ernst & Young has begun providing services effective immediately and is working with 3SBio and KPMG to ensure a seamless transition. The dismissal of KPMG and the appointment of Ernst & Young have been approved by the Audit Committee, with the concurrence of the Board of Directors of the Company.

The audit reports of KPMG on the effectiveness of internal control over financial reporting of 3SBio and its subsidiaries as of December 31, 2008, and the consolidated financial statements of 3SBio and subsidiaries as of and for the years ended December 31, 2007 and 2008 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com

    For more information, please contact:
    Investor Contact:
     Bo Tan, CFO
     3SBio Inc.
     Tel:   +86-24-2581-1820
     Email: Tanbo@3sbio.com
    Investor Relations (China):
     Peter Schmidt
     FD Beijing
     Tel:   +86-10-8591-1953
     Email: Peter.schmidt@fd.com
    Investor Relations (US):
     Evan Smith
     John Capodanno
     FD US
     Tel: +1-212-850-5600

SOURCE 3SBio Inc.